Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand potential correlates and ultimately mechanisms of protection against malaria disease. Cellular responses recognizing the RTS,S/AS01E-containing circumsporozoite protein (CSP) and Hepatitis B surface antigen (HBsAg) were assessed before and 1 month after primary vaccination by intracellular cytokine staining and 16-color flow cytometry in 105 RTS,S/AS01-vaccinated and 74 rabies-vaccinated participants (controls) in a pediatric phase III trial in Africa. RTS,S/AS01E-vaccinated children had signif...
RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African chil...
Background: The RTS,S/AS01E vaccine provides partial protection against malaria in African children,...
The candidate malaria vaccine RTS,S/AS01E provides significant but partial protection from clinical ...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed ...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
BACKGROUND: In a phase 3 trial in African infants and children, the RTS,S/AS01 vaccine (GSK) showed ...
In a phase 3 trial in African infants and children, the RTS,S/AS01 vaccine (GSK) showed moderate eff...
The RTS,S/AS01E vaccine targets the circumsporozoite protein (CSP) of the Plasmodium falciparum para...
Background The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children....
The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune ...
Background: Vaccination and naturally acquired immunity against microbial pathogens may have complex...
BACKGROUND: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being develo...
RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium falciparum, is undergoing clin...
RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African chil...
Background: The RTS,S/AS01E vaccine provides partial protection against malaria in African children,...
The candidate malaria vaccine RTS,S/AS01E provides significant but partial protection from clinical ...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed ...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand po...
BACKGROUND: In a phase 3 trial in African infants and children, the RTS,S/AS01 vaccine (GSK) showed ...
In a phase 3 trial in African infants and children, the RTS,S/AS01 vaccine (GSK) showed moderate eff...
The RTS,S/AS01E vaccine targets the circumsporozoite protein (CSP) of the Plasmodium falciparum para...
Background The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children....
The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune ...
Background: Vaccination and naturally acquired immunity against microbial pathogens may have complex...
BACKGROUND: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being develo...
RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium falciparum, is undergoing clin...
RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African chil...
Background: The RTS,S/AS01E vaccine provides partial protection against malaria in African children,...
The candidate malaria vaccine RTS,S/AS01E provides significant but partial protection from clinical ...